A Phase 1 interventional study of dabigatran etexilate and Ticagrelor in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-22.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
low dose dabigatran + high dose ticagrelor
Drug: Ticagrelor · Drug: dabigatran etexilate
high dose ticagrelor
Drug: Ticagrelor
medium dose dabigatran
Drug: dabigatran etexilate
low dose dabigatran
Drug: dabigatran etexilate
medium dose dabigatran
high dose ticagrelor
high dose ticagrelor
low dose dabigatran
medium dose dabigatran
Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.
Time frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours
Total Dabigatran: Maximum Measured Concentration (Cmax)
Maximum measured concentration of total dabigatran in plasma, per period.
Time frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours
Number of Participants With Drug Related Adverse Events
The number of participants with drug related adverse events
Time frame: From screening until the end-of-study examination
| Milestone | Dabigatran Etexilate 220 mg - Part 1 | Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 220 mg - Part 2 | Ticagrelor 180 mg - Part 2 | Dabigatran Etexilate/Multiple Dose Ticagrelor Crossover-Part 3 |
|---|---|---|---|---|---|
| Started | 8 | 4 | 8 | 4 | 12 |
| Completed | 8 | 4 | 8 | 4 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.
| ng*h/mL | Dabi 75 mg | Dabi + Ticagrelor LD | Dabi + Ticagrelor MD |
|---|---|---|---|
| Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) | 281.05 ± 104 | 485.48 ± 40.5 | 410.46 ± 53.1 |
Maximum measured concentration of total dabigatran in plasma, per period.
| ng/mL | Dabi 75 mg | Dabi + Ticagrelor LD | Dabi + Ticagrelor MD |
|---|---|---|---|
| Total Dabigatran: Maximum Measured Concentration (Cmax) | 31.47 ± 130 | 61.30 ± 42.9 | 49.11 ± 64.8 |
The number of participants with drug related adverse events
| participants | Dabigatran 220 mg - Part 1 | Ticagrelor 180 mg - Part 1 | Dabigatran 220 mg - Part 2 | Ticagrelor 180 mg - Part 2 | Dabigatran 75 mg - Part 3 | Dabigatran + Ticagrelor - Part 3 |
|---|---|---|---|---|---|---|
| Number of Participants With Drug Related Adverse Events | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over 3 to 10 days after last dosing. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate 220 mg - Part 1 | — | 0/8 (0%) | 1/8 (12.5%) |
| Ticagrelor 180 mg - Part 1 | — | 0/4 (0%) | 0/4 (0%) |
| Dabigatran Etexilate 220 mg - Part 2 | — | 0/8 (0%) | 0/8 (0%) |
| Ticagrelor 180 mg - Part 2 | — | 0/4 (0%) | 0/4 (0%) |
| Dabi 75 mg - Part 3 | — | 0/12 (0%) | 2/12 (16.7%) |
| Multiple Dose Ticagrelor - Part 3 | — | 0/12 (0%) | 3/12 (25%) |
| Event | Dabigatran Etexilate 220 mg - Part 1 | Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 220 mg - Part 2 | Ticagrelor 180 mg - Part 2 | Dabi 75 mg - Part 3 | Multiple Dose Ticagrelor - Part 3 |
|---|---|---|---|---|---|---|
| Gastrointestinal infectionInfections and infestations | 1/8 | 0/4 | 0/8 | 0/4 | 0/12 | 0/12 |
| NauseaGastrointestinal disorders | 0/8 | 0/4 | 0/8 | 0/4 | 0/12 | 1/12 |
| Neck painMusculoskeletal and connective tissue disorders | 0/8 | 0/4 | 0/8 | 0/4 | 1/12 | 1/12 |
| ErythemaSkin and subcutaneous tissue disorders | 0/8 | 0/4 | 0/8 | 0/4 | 0/12 | 1/12 |
| RashSkin and subcutaneous tissue disorders | 0/8 | 0/4 | 0/8 | 0/4 | 1/12 | 0/12 |
| Age Continuous(years) | Dabigatran Etexilate 220 mg - Part 1 | Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 220 mg - Part 2 | Ticagrelor 180 mg - Part 2 | Dabigatran Etexilate / Multiple Dose Ticagrelor - Part 3 | Total |
|---|---|---|---|---|---|---|
| Mean | 30.6 ± 7.7 | 29.8 ± 11.4 | 33.6 ± 9.1 | 33.3 ± 6.3 | 30.2 ± 7.2 | 31.3 ± 8.2 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate 220 mg - Part 1 | Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 220 mg - Part 2 | Ticagrelor 180 mg - Part 2 | Dabigatran Etexilate / Multiple Dose Ticagrelor - Part 3 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 8 | 4 | 8 | 4 | 12 | 36 |
The record gives a start of May 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor